The endocrine disruptor mono-(2-ethylhexyl) phthalate affects the differentiation of human liposarcoma cells (SW 872)

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Campioli, Enrico ^a,b   Batarseh, Amani ^a   Li, Jiehan ^a   Papadopoulos, Vassilios ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COA CARBOXYLASE ALPHA; ACETYL COENZYME A CARBOXYLASE; ADENOSINE TRIPHOSPHATE CITRATE LYASE; BINDING PROTEIN; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHTHALIC ACID 2 ETHYLHEXYL MONOESTER; PROTEIN TSPO; S100 CALCIUM BINDING PROTEIN B; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR; BIOLOGICAL MARKER; BROXURIDINE; DRUG DERIVATIVE; ENDOCRINE DISRUPTOR; MONO (2 ETHYLHEXYL)PHTHALATE; MONO-(2-ETHYLHEXYL)PHTHALATE; PHORBOL 13 ACETATE 12 MYRISTATE; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PROTEIN KINASE C EPSILON; TSPO PROTEIN, HUMAN;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPOSARCOMA; PROADIPOCYTE; PROTEIN FUNCTION; SARCOMA CELL; ADIPOCYTE; ANIMAL; CELL STRAIN 3T3; CYTOLOGY; DRUG EFFECT; GENE SILENCING; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; BIOLOGICAL MARKERS; BROMODEOXYURIDINE; CELL DIFFERENTIATION; CELL LINE, TUMOR; DIETHYLHEXYL PHTHALATE; ENDOCRINE DISRUPTORS; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIPOSARCOMA; MICE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROTEIN KINASE C-EPSILON; RECEPTORS, GABA; RNA, MESSENGER; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION, GENETIC;

EID: 83755225151     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028750     Document Type: Article

References (58)

1. Halden RU, (2010) Plastics and health risks. Annu Rev Public Health 31: 179-94.
2. Fromme H, Lahrz T, Piloty M, Gebhart H, Oddoy A, et al. (2004) Occurrence of phthalates and musk fragrances in indoor air and dust from apartments and kindergartens in Berlin (Germany). Indoor Air 14: 188-95.
3. Rudel RA, Perovich LJ, (2009) Endocrine disrupting chemicals in indoor and outdoor air. Atmos Environ 43: 170-181.
4. Agency for Toxic Substances and Disease Registry (ATSDR) (1993) Toxicological Profile for Di(2-ethylhexyl)phthalate. Public Health Service, U.S. Department of Health and Human Services, Atlanta, GA. Available: http://www.atsdr.cdc.gov/substances/toxsubstance.asp?toxid=65. Accessed 2011 Jul 14.
5. Health Canada report (2001) DEHP in Medical Devices. Available: http://www.hc-sc.gc.ca/dhp-mps/md-im/activit/sci-consult/dehp/sapdehp_rep_gcsdehp_rap_2001-04-26-eng.php#1.3. Accessed 2011 Jul 14.
6. Huber WW, Grasl-Kraupp B, Schulte-Hermann R, (1996) Hepatocarcinogenic potential of di(2-ethylhexyl)phthalate in rodents and its implications on human risk. Crit Rev Toxicol 26: 365-481.
7. National Toxicology Program U.S. Department of Health and Human Services, Center For The Evaluation Of Risks To Human Reproduction (2006) NTP-CERHR Monograph on the Potential Human Reproductive and Developmental Effects of Di(2-Ethylhexyl) Phthalate (DEHP). NIH Publication no. 06-4476. Available: http://ntp.niehs.nih.gov/ntp/ohat/phthalates/dehp/DEHP-Monograph.pdf. Accessed 2011 Jul 14.
8. Frederiksen H, Skakkebaek NE, Andersson AM, (2007) Metabolism of phthalates in humans. Mol Nutr Food Res 51: 899-911.
9. Rock G, Labow RS, Tocchi M, (1986) Distribution of di(2-ethylhexyl) phthalate and products in blood and blood components. Environ Health Perspect 65: 309-16.
10. Duty SM, Silva MJ, Barr DB, Brock JW, Ryan L, et al. (2003) Phthalate exposure and human semen parameters. Epidemiology 14: 269-77.
11. Calafat AM, Slakman AR, Silva MJ, Herbert AR, Needham LL, (2004) Automated solid phase extraction and quantitative analysis of human milk for 13 phthalate metabolites. J Chromatogr B Analyt Technol Biomed Life Sci 805: 49-56.
12. Dreyer C, Keller H, Mahfoudi A, Laudet V, Krey G, et al. (1993) Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biol Cell 77: 67-76.
13. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, et al. (1993) Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 90: 2160-4.
14. Kersten S, Desvergne B, Wahli W, (2000) Roles of PPARs in health and disease. Nature 405: 421-4.
15. Braissant O, Foufelle F, Scotto C, Dauça M, Wahli W, (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha,-beta, and-gamma in the adult rat. Endocrinology 137: 354-66.
16. Ribet C, Montastier E, Valle C, Bezaire V, Mazzucotelli A, et al. (2010) Peroxisome proliferator-activated receptor-alpha control of lipid and glucose metabolism in human white adipocytes. Endocrinology 151: 123-33.
17. Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, et al. (2003) The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol 17: 2477-93.
18. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, et al. (2001) Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol 154: 799-814.
19. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J, (1997) Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem 272: 28210-7.
20. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA, (1994) Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135: 798-800.
21. Brun RP, Tontonoz P, Forman BM, Ellis R, Chen J, et al. (1996) Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev 10: 974-84.
22. Sarafidis PA, Lasaridis AN, (2006) Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect. Am J Hypertens 19: 646-653.
23. Ondrey F, (2009) Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res 15: 2-8.
24. Gazouli M, Yao ZX, Boujrad N, Corton JC, Culty M, et al. (2002) Effect of peroxisome proliferators on Leydig cell peripheral-type benzodiazepine receptor gene expression, hormone-stimulated cholesterol transport, and steroidogenesis: role of the peroxisome proliferator-activated receptor α. Endocrinolgy 143: 2571-83.
25. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapère JJ, et al. (2006) Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 27: 402-9.
26. Batarseh A, Papadopoulos V, (2010) Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states. Mol Cell Endocrinol 327: 1-12.
27. Batarseh A, Li J, Papadopoulos V, (2010) Protein kinase Cepsilon regulation of translocator protein (18 kDa) Tspo gene expression is mediated through a MAPK pathway targeting STAT3 and c-Jun transcription factors. Biochemistry 49: 4766-78.
28. Batarseh A, Giatzakis C, Papadopoulos V, (2008) Phorbol-12-myristate 13-acetate acting through protein kinase Cepsilon induces translocator protein (18-kDa) TSPO gene expression. Biochemistry 47: 12886-99.
29. Wade FM, Wakade C, Mahesh VB, Brann DW, (2005) Differential expression of the peripheral benzodiazepine receptor and gremlin during adipogenesis. Obes Res 13: 818-22.
30. Gonzalez Solveyra C, Romeo HE, Rosenstein RE, Estevez AG, Cardinali DP, (1988) Benzodiazepine binding sites in rat interscapular brown adipose tissue: effect of cold environment, denervation and endocrine ablations. Life Sci 42: 393-402.
31. Campioli E, Carnevale G, Avallone R, Guerra D, Baraldi M, (2011) Morphological and Receptorial Changes in the Epididymal Adipose Tissue of Rats Subjected to a Stressful Stimulus. Obesity 19: 703-8.
32. Carmel JF, Tarnus E, Cohn JS, Bourdon E, Davignon J, et al. (2009) High expression of apolipoprotein E impairs lipid storage and promotes cell proliferation in human adipocytes. J Cell Biochem 106: 608-17.
33. Li H, Yao Z, Degenhardt B, Teper G, Papadopoulos V, (2001) Cholesterol binding at the cholesterol recognition/interaction amino acid consensus (CRAC) of the peripheral-type benzodiazepine receptor and inhibition of steroidogenesis by an HIV TAT-CRAC peptide. Proc Natl Acad Sci USA 98: 1267-1272.
34. Ailhaud G, Grimaldi P, Négrel R, (1992) Cellular and molecular aspects of adipose tissue development. Annu Rev Nutr 12: 207-33.
35. Michetti F, Dell'Anna E, Tiberio G, Cocchia D, (1983) Immunochemical and immunocytochemical study of S-100 protein in rat adipocytes. Brain Res 262: 352-6.
36. Kato K, Suzuki F, Ogasawara N, (1988) Induction of S100 protein in 3T3-L1 cells during differentiation to adipocytes and its liberating by lipolytic hormones. Eur J Biochem 177: 461-6.
37. Ramji DP, Foka P, (2002) CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J 365: 561-75.
38. Smyth MJ, Sparks RL, Wharton W, (1993) Preadipocyte cell lines: models of cellular proliferation and differentiation. J Cell Sci 106: 1-9.
39. Izem L, Morton RE, (2001) Cholesteryl ester transfer protein biosynthesis and cellular cholesterol homeostasis are tightly interconnected. J Biol Chem 276: 26534-41.
40. Wassef H, Bernier L, Davignon J, Cohn JS, (2004) Synthesis and secretion of apoC-I and apoE during maturation of human SW872 liposarcoma cells. J Nutr 134: 2935-41.
41. Papadopoulos V, Boujrad N, Ikonomovic MD, Ferrara P, Vidic B, (1994) Topography of the Leydig cell mitochondrial peripheral-type benzodiazepine receptor. Mol Cell Endocrinol 104: R5-9.
42. Delavoie F, Li H, Hardwick M, Robert JC, Giatzakis C, et al. (2003) In vivo and in vitro peripheral-type benzodiazepine receptor polymerization: functional significance in drug ligand and cholesterol binding. Biochemistry 42: 4506-19.
43. Rubin RJ, Jaeger RJ, (1973) Some pharmacologic and toxicologic effects of di-2-ethylhexyl phthalate (DEHP) and other plasticizers. Environ Hlth Perspect 3: 53-59.
44. Gesler RM, (1973) Toxicology of Di-2-ethylhexyl phthalate and other phthalic acid ester plasticizers. Environ Hlth Perspect 3: 73-79.
45. Kluwe WM, McConell EE, Huff JE, Haseman JK, Douglas JF, et al. Carcinogenicity testing of phthalate esters and related compounds by the National Toxicology Program and the National Cancer Institute. Environ Hlth Perspect 45: 129-133.
46. Tomita I, Nakamura Y, Aoki N, Inui N, (1982) Mutagenic/carcinogenic potential of DEHP and MEHP. Environ Hlth Perspect 45: 119-125.
47. Dillingham EO, Autian J, (1973) Teratogenicity, and Cellular toxicity of phthalate esters. Environ Hlth Perspect 3: 81-94.
48. Autian J, (1982) Antifertility effects and dominant lethal assays for mutagenic effects of DEHP. Environ Hlth Perspect; 45: 115-118.
49. Singh AR, Lawrence WH, Autian J, (1974) Mutagenic and antifertility sensitivities of mice to di-(2-ethylhexyl) phthalate (DEHP) and dimethoxyethyl phthalate (DMEP). Toxicol Appl Pharmacol 29: 35-36.
50. Culty M, Thuillier R, Li W, Wang Y, Martinez-Arguelles DB, et al. (2008) In utero exposure to di-(2-ethylhexyl) phthalate exerts both short-term and long-lasting suppressive effects on testosterone production in the rat. Biol Reprod 78: 1018-28.
51. Dees JH, Gazouli M, Papadopoulos V, (2001) Effect of mono-ethylhexyl phthalate on MA-10 Leydig tumor cells. Reprod Toxicol 15: 171-87.
52. Feige JN, Gelman L, Rossi D, Zoete V, Métivier R, et al. (2007) The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor γ modulator that promotes adipogenesis. J Biol Chem 282: 19152-66.
53. Orellana A, Hidalgo PC, Morales MN, Mezzano D, Bronfman M, (1990) Palmitoyl-CoA and the acyl-CoA thioester of the carcinogenic peroxisome-proliferator ciprofibrate potentiate diacylglycerol-activated protein kinase C by decreasing the phosphatidylserine requirement of the enzyme. Eur J Biochem 190: 57-61.
54. Reza JZ, Doosti M, Salehipour M, Packnejad M, Mojarrad M, et al. (2009) Modulation peroxisome proliferators activated receptor alpha (PPAR alpha) and acyl coenzyme A: cholesterol acyltransferase1 (ACAT1) gene expression by fatty acids in foam cell. Lipids Health Dis 8: 38.
55. Zhao Y, Okuyama M, Hashimoto H, Tagawa Y, Jomori T, et al. (2010) Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor alpha signaling. Toxicol In Vitro 24: 154-9.
56. Sell H, Berger JP, Samson P, Castriota G, Lalonde J, et al. (2004) Peroxisome proliferator-activated receptor gamma agonism increases the capacity for sympathetically mediated thermogenesis in lean and ob/ob mice. Endocrinology 145: 3925-34.
57. Nofziger C, Brown KK, Smith CD, Harrington W, Murray D, et al. (2009) PPARγ agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line. Am J Physiol Renal Physiol 297: F55-62.
58. De Pauw A, Tejerina S, Raes M, Keijer J, Arnould T, (2009) Mitochondrial (dys)function in adipocyte (de)differentiation and systemic metabolic alterations. Am J Pathol 175: 927-939.